A Cost–Benefit Analysis of COVID-19 Vaccination in Catalonia
Francesc López Seguí(Universitat de Vic - Universitat Central de Catalunya), Jordi Ara, Oriol Estrada, Bonaventura Clotet(IrsiCaixa), Martí Català(Nuffield Orthopaedic Centre), Clara Prats(Universitat Politècnica de Catalunya), Roser Vallès, Marc Vilar, Núria Prat, Josep María Argimón(Ministry of Health), Irene Oliva(Universitat Pompeu Fabra), Mar Isnard, Anna Aran(Ministry of Health)
Cited by 28
Related Papers
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
|The Lancet Infectious Diseases|2011|172
The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia
|The Lancet Respiratory Medicine|2024|166
Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2005|151